The ATRA‐mediated enhancement of tumor response to anti‐PD‐1 treatment relies on the existence of OTUD6B mRNA, since in OTUD6B‐knockdown ESCC tumors, ATRA could not improve the effects of anti‐PD‐1 immunotherapy (Figure 7J,K). The gene discussed is OTUD6B; the disease is neoplasm.